Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
=== Pharmacokinetics === There are no clinical studies of the pharmacokinetics of 4-AcO-DMT as of 2024. However, the pharmacokinetics of 4-AcO-DMT have been studied in rodents. The drug was confirmed to act as a prodrug of psilocin similarly to psilocybin (4-PO-DMT). However, given by intraperitoneal injection at equimolar doses, 4-AcO-DMT showed only 70% of the relative bioavailability or total exposure of psilocybin. Hence, 4-AcO-DMT results in modestly lower psilocin levels than psilocybin even when the drugs are given at equivalent doses with adjustment for differences in molecular weight. Along similar lines, the psilocin concentrations with 4-AcO-DMT 15 minutes after administration were 75 to 90% of those of an equimolar dose of psilocybin. The elimination half-life of psilocin was approximately 30 minutes and did not differ between 4-AcO-DMT and psilocybin. Psilocin ester prodrugs like 4-AcO-DMT are cleaved into psilocin by esterase enzymes. A 2025 in-vitro study examined the stability and metabolism of several psilocin ester prodrugs, including 4-AcO-DMT. The results showed that 4-AcO-DMT was rapidly broken down into psilocin by esterase enzymes, with over 99.9% of the prodrug converted within 5 minutes under conditions mimicking the human body (i.e., in human plasma). These findings support the idea that 4-AcO-DMT is quickly and efficiently converted into psilocin before it enters the bloodstream, and that the prodrug itself likely contributes little to the overall pharmacological effect.
Mothers who take certain recreational drugs should not breastfeed, however, most medications are compatible with breastfeeding. Available evidence indicates that it is unlikely that COVID-19 can be transmitted through breast milk. Smoking tobacco and consuming limited amounts of alcohol or coffee are not reasons to avoid breastfeeding.
Long-chain-fatty-acid—CoA ligase catalyzes the reaction between a fatty acid with ATP to give a fatty acyl adenylate, plus inorganic pyrophosphate, which then reacts with free coenzyme A to give a fatty acyl-CoA ester and AMP. If the fatty acyl-CoA has a long chain, then the carnitine shuttle must be utilized (shown in the table below): Acyl-CoA is transferred to the hydroxyl group of carnitine by carnitine palmitoyltransferase I, located on the cytosolic faces of the outer and inner mitochondrial membranes. Acyl-carnitine is shuttled inside by a carnitine-acylcarnitine translocase, as a carnitine is shuttled outside. Acyl-carnitine is converted back to acyl-CoA by carnitine palmitoyltransferase II, located on the interior face of the inner mitochondrial membrane. The liberated carnitine is shuttled back to the cytosol, as an acyl-carnitine is shuttled into the matrix. If the fatty acyl-CoA contains a short chain, these short-chain fatty acids can simply diffuse through the inner mitochondrial membrane.
Sources: en.wikipedia.org
=== Neuroanatomy === Nociceptin controls a wide range of biological functions ranging from nociception to food intake, from memory processes to cardiovascular and renal functions, from spontaneous locomotor activity to gastrointestinal motility, from anxiety to the control of neurotransmitter release at peripheral and central sites.
Naram-Sin's Victory Stele depicts him as a god-king (symbolized by his horned helmet) climbing a mountain above his soldiers, and his enemies, the defeated Lullubi led by their king Satuni. The stele was broken off at the top apparently when it was carried away from Sippar and carried off by the Elamite forces of Shutruk-Nakhunte in the 12th century BC along with a number of other monuments. The stele seems to break from tradition by using successive diagonal tiers to communicate the story to viewers, however the more traditional horizontal frames are visible on smaller broken pieces. It has been suggested that it contains the first depictions of battle standards and plate armor. The stele is 2 meters tall and 1.05 meters wide and is made from pinkish limestone. For contrast, see the Victory Stele of Rimush over Lagash or the Victory stele of Sargon. The stele was found by Jacques de Morgan at Susa, and is now in the Louvre Museum (Sb 4). The inscription over the head of the king is in the Akkadian language and very fragmentary, but reads:
== Examples == The following is a list of human proteins containing the protein kinase domain: AAK1 ; AATK ; ABL1 ; ABL2 ; ACVR1 ; ACVR1B ; ACVR1C ; ACVR2A ; ACVR2B ; ACVRL1 ; AKT1 ; AKT2 ; AKT3 ; ALK ; AMHR2 ; ANKK1 ; ARAF ; AURKA ; AURKB ; AURKC ; AXL ; BLK ; BMP2K ; BMPR1A ; BMPR1B ; BMPR2 ; BMX ; BRAF ; BRSK1 ; BRSK2 ; BTK ; BUB1 ; BUB1B ; CAMK1 ; CAMK1D ; CAMK1G ; CAMK2A ; CAMK2B ; CAMK2D ; CAMK2G ; CAMK4 ; CAMKK1 ; CAMKK2 ; CAMKV ; CASK ; CDC42BPA ; CDC42BPB ; CDC42BPG ; CDC7 ; CDK1 ; CDK10 ; CDK11A ; CDK11B ; CDK12 ; CDK13 ; CDK14 ; CDK15 ; CDK16 ; CDK17 ; CDK18 ; CDK19 ; CDK2 ; CDK20 ; CDK3 ; CDK4 ; CDK5 ; CDK6 ; CDK7 ; CDK8 ; CDK9 ; CDKL1 ; CDKL2 ; CDKL3 ; CDKL4 ; CDKL5 ; CHEK1 ; CHEK2 ; CHUK ; CIT ; CLK1 ; CLK2 ; CLK3 ; CLK4 ; CSF1R ; CSK ; CSNK1A1 ; CSNK1A1L ; CSNK1D ; CSNK1E ; CSNK1G1 ; CSNK1G2 ; CSNK1G3 ; CSNK2A1 ; CSNK2A2 ; CSNK2A3 ; DAPK1 ; DAPK2 ; DAPK3 ; DCLK1 ; DCLK2 ; DCLK3 ; DDR1 ; DDR2 ; DMPK ; DSTYK ; DYRK1A ; DYRK1B ; DYRK2 ; DYRK3 ; DYRK4 ; EGFR ; EIF2AK1 ; EIF2AK2 ; EIF2AK3 ; EIF2AK4 ; EPHA1 ; EPHA10 ; EPHA2 ; EPHA3 ; EPHA4 ; EPHA5 ; EPHA6 ; EPHA7 ; EPHA8 ; EPHB1 ; EPHB2 ; EPHB3 ; EPHB4 ; EPHB6 ; ERBB2 ; ERBB3 ; ERBB4 ; ERN1 ; ERN2 ; FER ; FES ; FGFR1 ; FGFR2 ; FGFR3 ; FGFR4 ; FGR ; FLT1 ; FLT3 ; FLT4 ; FRK ; FYN ; GAK ; GRK1 ; GRK2 ; GRK3 ; GRK4 ; GRK5 ; GRK6 ; GRK7 ; GSG2 ; GSK3A ; GSK3B ; GUCY2C ; GUCY2D ; GUCY2F ; HCK ; HIPK1 ; HIPK2 ; HIPK3 ; HIPK4 ; HUNK ; ICK ; IGF1R ; IKBKB ; IKBKE ; ILK ; INSR ; INSRR ; IRAK1 ; IRAK2 ; IRAK3 ; IRAK4 ; ITK ; JAK1 ; JAK2 ; JAK3 ; KALRN ; KDR ; KIT ; KSR1 ; KSR2 ; LATS1 ; LATS2 ; LCK ; LIMK1 ; LIMK2 ; LMTK2 ; LMTK3 ; LRRK1 ; LRRK2 ; LTK ; LYN ; MAK ; MAP2K1 ; MAP2K2 ; MAP2K3 ; MAP2K4 ; MAP2K5 ; MAP2K6 ; MAP2K7 ; MAP3K1 ; MAP3K10 ; MAP3K11 ; MAP3K12 ; MAP3K13 ; MAP3K14 ; MAP3K15 ; MAP3K19 ; MAP3K2 ; MAP3K20 ; MAP3K21 ; MAP3K3 ; MAP3K4 ; MAP3K5 ; MAP3K6 ; MAP3K7 ; MAP3K8 ; MAP3K9 ; MAP4K1 ; MAP4K2 ; MAP4K3 ; MAP4K4 ; MAP4K5 ; MAPK1 ; MAPK10 ; MAPK11 ; MAPK12 ; MAPK13 ; MAPK14 ; MAPK15 ; MAPK3 ; MAPK4 ; MAPK6 ; MAPK7 ; MAPK8 ; MAPK9 ; MAPKAPK2 ; MAPKAPK3 ; MAPKAPK5 ; MARK1 ; MARK2 ; MARK3 ; MARK4 ; MAST1 ; MAST2 ; MAST3 ; MAST4 ; MASTL ; MATK ; MELK ; MERTK ; MET ; MINK1 ; MKNK1 ; MKNK2 ; MLKL ; MOK ; MOS ; MST1R ; MUSK ; MYLK ; MYLK2 ; MYLK3 ; MYLK4 ; MYO3A ; MYO3B ; NEK1 ; NEK10 ; NEK11 ; NEK2 ; NEK3 ; NEK4 ; NEK5 ; NEK6 ; NEK7 ; NEK8 ; NEK9 ; NIM1K ; NLK ; NPR1 ; NPR2 ; NRBP1 ; NRBP2 ; NRK ; NTRK1 ; NTRK2 ; NTRK3 ; NUAK1 ; NUAK2 ; OBSCN ; OXSR1 ; PAK1 ; PAK2 ; PAK3 ; PAK4 ; PAK5 ; PAK6 ; PAN3 ; PASK ; PBK ; PDGFRA ; PDGFRB ; PDIK1L ; PDPK1 ; PDPK2P ; PEAK1 ; PEAK3 ; PHKG1 ; PHKG2 ; PIK3R4 ; PIM1 ; PIM2 ; PIM3 ; PINK1 ; PKDCC ; PKMYT1 ; PKN1 ; PKN2 ; PKN3 ; PLK1 ; PLK2 ; PLK3 ; PLK4 ; PLK5 ; PNCK ; POMK ; PRKAA1 ; PRKAA2 ; PRKACA ; PRKACB ; PRKACG ; PRKCA ; PRKCB ; PRKCD ; PRKCE ; PRKCG ; PRKCH ; PRKCI ; PRKCQ ; PRKCZ ; PRKD1 ; PRKD2 ; PRKD3 ; PRKG1 ; PRKG2 ; PRKX ; PRKY ; PRPF4B ; PSKH1 ; PSKH2 ; PTK2 ; PTK2B ; PTK6 ; PTK7 ; PXK ; RAF1 ; RET ; RIOK1 ; RIOK2 ; RIOK3 ; RIPK1 ; RIPK2 ; RIPK3 ; RIPK4 ; RNASEL ; ROCK1 ; ROCK2 ; ROR1 ; ROR2 ; ROS1 ; RPS6KA1 ; RPS6KA2 ; RPS6KA3 ; RPS6KA4 ; RPS6KA5 ; RPS6KA6 ; RPS6KB1 ; RPS6KB2 ; RPS6KC1 ; RPS6KL1 ; RSKR ; RYK ; SBK1 ; SBK2 ; SBK3 ; SCYL1 ; SCYL2 ; SCYL3 ; SGK1 ; SGK2 ; SGK223 ; SGK3 ; SIK1 ; SIK1B ; SIK2 ; SIK3 ; SLK ; SNRK ; SPEG ; SRC ; SRMS ; SRPK1 ; SRPK2 ; SRPK3 ; STK10 ; STK11 ; STK16 ; STK17A ; STK17B ; STK24 ; STK25 ; STK26 ; STK3 ; STK31 ; STK32A ; STK32B ; STK32C ; STK33 ; STK35 ; STK36 ; STK38 ; STK38L ; STK39 ; STK4 ; STK40 ; STKLD1 ; STRADA ; STRADB ; STYK1 ; SYK ; TAOK1 ; TAOK2 ; TAOK3 ; TBCK ; TBK1 ; TEC ; TEK ; TESK1 ; TESK2 ; TEX14 ; TGFBR1 ; TGFBR2 ; TIE1 ; TLK1 ; TLK2 ; TNIK ; TNK1 ; TNK2 ; TNNI3K ; TP53RK ; TRIB1 ; TRIB2 ; TRIB3 ; TRIO ; TSSK1B ; TSSK2 ; TSSK3 ; TSSK4 ; TSSK6 ; TTBK1 ; TTBK2 ; TTK ; TTN ; TXK ; TYK2 ; TYRO3 ; UHMK1 ; ULK1 ; ULK2 ; ULK3 ; ULK4 ; VRK1 ; VRK2 ; VRK3 ; WEE1 ; WEE2 ; WNK1 ; WNK2 ; WNK3 ; WNK4 ; YES1 ; ZAP70
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.